Minutes from the Annual General Meeting in Cessatech A/S

Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its Annual General Meeting on Wednesday 27 March 2023 at 09:00 (CET) at the Company's address Kanonbådsvej 2, 1437 København K.

The agenda for the general meeting was as follows:

1. ELECTION OF CHAIRMAN OF THE MEETING
   1. Mikkel Rostock-Jensen was elected chairman of the meeting. The chairman of the meeting ascertained that none of the shareholders objected to the legality of the annual general meeting and announced that the annual general meeting had been duly convened and was legal and competent in terms of all items on the agenda. The chairman of the general meeting then informed that based on postal votes and proxies duly received prior to the general meeting a solid support of all proposals on the agenda had been secured in advance of the meeting.

2. REPORT ON THE ACTIVITIES OF THE COMPANY IN THE PAST FINANCIAL YEAR
   1. The report on the Company’s activities in 2023 was noted by the general meeting.

3. PRESENTATION OF THE ANNUAL REPORT WITH AUDITORS’ REPORT FOR ADOPTION
   1. The general meeting unanimously adopted the audited annual report with auditors’ report for 2023.

4. RESOLUTION ON COVERING OF LOSSES IN ACCORDANCE WITH THE ADOPTED ANNUAL REPORT
   1. The general meeting unanimously resolved that the consolidated loss for the financial year 2023 of tDKK 22,510 is carried forward to the next financial year in accordance with the adopted annual report.

5. ELECTION OF MEMBERS TO THE BOARD OF DIRECTORS
   1. The general meeting unanimously decided to re-elect Martin Olin, Peter Birk, Charlotte Videbæk, Flemming Steen Jensen and Rachel Curtis Gravesen. For the purpose of these minutes, it is noted that the board of directors subsequently elected Martin Olin as chairman of the board.

6. ELECTION OF AUDITOR
   1. The general meeting unanimously re-elected PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab, CVR no. 41293055, as the Company’s auditor

7. PROPOSALS FROM THE BOARD OF DIRECTORS AND SHAREHOLDERS
   1. Prolongation of the authorisation to increase the share capital

The board of directors adopted to prolong the existing authorization of clause 3.2.1 so that it expires on 23 March 2029 and to make an adjustment (for clarification purposes only) to the wording as stated below:

3.2.1. Authorization to cash increase of the share capital: In the period until 23 March 2029, the board of directors is authorized to increase the Company’s share capital in one or more issues of new shares at a price equal to market price with-out pre-emption rights for the Company’s existing shareholders by up to a nominal amount of DKK 4,635,075.

The chairman of the general meeting announced that all the agenda items had been discussed and announced that the annual general meeting had come to an end.

The adopted articles of association were made available on the Company's website after the annual general meeting.

- 0 -

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.